Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company pioneering engineered T cell therapies for autoimmune diseases. This page serves as the definitive source for official updates on clinical trials, research advancements, and corporate developments related to their innovative CAART and CARTA platforms.
Investors and researchers will find curated press releases detailing progress across multiple Phase 1/2 trials targeting conditions including lupus, myositis, and pemphigus vulgaris. Our collection features updates on therapeutic mechanisms that selectively eliminate pathogenic B cells while preserving healthy immune function.
The resource covers essential developments including trial design innovations, manufacturing process improvements, and strategic collaborations. All content is rigorously verified to ensure accuracy in reporting on this cutting-edge approach to autoimmune treatment.
Bookmark this page for streamlined access to Cabaletta Bio's latest milestones in developing potentially curative therapies. Check regularly for updates on clinical programs demonstrating the company's commitment to transforming autoimmune disease management.
Cabaletta Bio (Nasdaq: CABA) announced the successful clearance of its IND application for CABA-201, a CAR T cell therapy targeting systemic lupus erythematosus (SLE) and lupus nephritis (LN), by the FDA. This milestone was achieved within six months post-licensing, reflecting an efficient clinical trial design informed by prior data. The planned Phase 1/2 trial aims to evaluate the efficacy and safety of CABA-201, with initial results expected by mid-2024. SLE primarily affects young women and poses significant health risks, impacting an estimated 160,000-320,000 patients in the U.S.
Cabaletta Bio (CABA) anticipates Investigational New Drug (IND) clearance for its CABA-201 treatment by mid-2023, with clinical data expected by mid-2024. This fully human CD19-CAR T therapy targets autoimmune diseases and has shown promising preclinical results. The company announced a net revenue of $32.6 million from a public offering in December 2022. R&D expenses rose to $39.3 million for 2022, up from $32.5 million in 2021, while general and administrative costs also increased. Despite these expenses, Cabaletta's cash reserves stood at $106.5 million as of December 31, 2022, ensuring operational funding through Q1 2025.
On February 28, 2023, Cabaletta Bio (Nasdaq: CABA) announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference. This event is set for March 7, 2023, at 2:10 p.m. ET in Boston, MA. A live webcast will be accessible on the company’s website, with replays available for 30 days post-event.
Cabaletta Bio focuses on developing innovative T cell therapies aimed at treating autoimmune diseases. Their CABA™ platform includes the CARTA and CAART strategies, with promising candidates like CABA-201 and DSG3-CAART, which may offer curative solutions for various conditions.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that CEO Steven Nichtberger will present at the 41st Annual J.P. Morgan Conference on January 12th at 7:30 a.m. PT in San Francisco. A live webcast will be available on the company’s website, and replays will be accessible for 30 days. Cabaletta Bio aims to develop potentially curative therapies through its CABA™ platform, which includes lead candidates CABA-201 and DSG3-CAART for conditions like mucosal pemphigus vulgaris.
Cabaletta Bio, a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, has announced an underwritten public offering of pre-funded warrants and common stock. The offering aims to sell 6,213,776 pre-funded warrants at $5.51999 each and 126,815 shares of common stock at $5.52, totaling expected gross proceeds of approximately $35 million. The offering, which is oversubscribed and backed by prominent investors, is set to close on December 12, 2022. Proceeds will fund the clinical development of CABA-201 and other ongoing studies.
Cabaletta Bio (Nasdaq: CABA) announced that Dr. Steven Nichtberger will join a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will provide insights into the company's efforts in developing curative targeted cell therapies for autoimmune diseases, including engineered T cell therapies. A live webcast will be accessible on the company's website, with replays available for 30 days afterward. Cabaletta Bio is headquartered in Philadelphia, PA.
Cabaletta Bio, Inc. (Nasdaq: CABA) reported its third-quarter financial results for 2022, highlighting progress in its clinical development of innovative cell therapies for autoimmune diseases. The company plans to submit an IND for CABA-201 in the first half of 2023, with initial data expected by early 2024. Financials show R&D expenses of $8.2 million, unchanged year-over-year, and G&A costs at $3.6 million, up slightly. Cash reserves decreased to $85.9 million from $122.2 million, projecting funds through mid-2024. Regulatory incentives were noted for MuSK-CAART, enhancing future growth prospects.
Cabaletta Bio has announced a global license for a fully human CD19 binder for autoimmune disease treatment. The CABA-201 Investigational New Drug (IND) application is expected in the first half of 2023, with initial clinical data anticipated by mid-2024, subject to IND approval. This development is informed by a partnership with Dr. Georg Schett, a leader in CD19-targeting therapies. The collaboration aims to enhance understanding of immunologic responses in autoimmune conditions. CABA-201 has the potential to address diseases like systemic lupus erythematosus and rheumatoid arthritis.
Cabaletta Bio, focused on developing targeted cell therapies for autoimmune diseases, will present data from the DesCAARTes™ trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris at the 29th Annual Congress of the European Society of Gene & Cell Therapy in Edinburgh from October 11-14, 2022.
The poster, titled 'Characterization of DSG3-CAART cells prior to & following adoptive transfer in mucosal Pemphigus Vulgaris,' will be presented on October 13, 2022, by Dr. Samik Basu. More information will be available on the ESGCT website and Cabaletta’s own site post-presentation.
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology firm, announced that CEO Steven Nichtberger, M.D., will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 3, 2022, at 4:00 p.m. ET in New York. The event will be webcast live, and a replay will be available for 30 days on their website. Cabaletta Bio specializes in engineered T cell therapies aimed at treating autoimmune diseases, with a pipeline focusing on conditions like pemphigus vulgaris and myasthenia gravis.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
